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Abstract
Background: Methotrexate treatment has been associated to intestinal epithelial damage. Studies have suggested
an important role of nitric oxide in such injury. The aim of this study was to investigate the role of nitric oxide
(NO), specifically iNOS on the pathogenesis of methotrexate (MTX)-induced intestinal mucositis.
Methods: Intestinal mucositis was carried out by three subcutaneous MTX injections (2.5 mg/kg) in Wistar rats and
in inducible nitric oxide synthase knock-out (iNOS
-/-) and wild-type (iNOS
+/+) mice. Rats were treated
intraperitoneally with the NOS inhibitors aminoguanidine (AG; 10 mg/Kg) or L-NAME (20 mg/Kg), one hour before
MTX injection and daily until sacrifice, on the fifth day. The jejunum was harvested to investigate the expression of
Ki67, iNOS and nitrotyrosine by immunohistochemistry and cell death by TUNEL. The neutrophil activity by
myeloperoxidase (MPO) assay was performed in the three small intestine segments.
Results: AG and L-NAME significantly reduced villus and crypt damages, inflammatory alterations, cell death, MPO
activity, and nitrotyrosine immunostaining due to MTX challenge. The treatment with AG, but not L-NAME,
prevented the inhibitory effect of MTX on cell proliferation. MTX induced increased expression of iNOS detected by
immunohistochemistry. MTX did not cause significant inflammation in the iNOS
-/- mice.
Conclusion: These results suggest an important role of NO, via activation of iNOS, in the pathogenesis of intestinal
mucositis.
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1. Background
Mucositis is a debilitating side effect of cytotoxic che-
motherapy and radiotherapy. It involves inflammation
and mucosal ulceration of the alimentary tract, resulting
in symptoms including pain, abdominal bloating, nausea,
vomiting and diarrhea, and may significantly impair
treatment compliance [1,2].
It has been demonstrated that methotrexate (MTX), an
inhibitor of dihydrofolate reductase and of DNA synth-
esis, can disrupt the intestinal epithelial barrier [3], lead-
ing to mitotic arrest in the crypts and villous blunting
[4,5]. The main mechanism behind the development of
mucositis was considered to be the result of direct cyto-
toxic effects of chemotherapy or radiotherapy on the
basal cells of the epithelium because of its high cell turn-
over rate. Subsequently, researchers investigating intest-
inal damage, found that, following radiation, the primary
damage response occurred in endothelial cells [6,7]. It is
postulated that mucositis occurs in five overlapping
phases: initiation, up-regulation and message generations,
signaling and amplification, ulceration and healing. [2,8].
Cytokines have been shown to stimulate the expression
of the inducible NOS synthase isoform (iNOS) with conse-
quent production of nitric oxide (NO). Nitric oxide (NO)
is a free radical associated with a multitude of physiologi-
cal functions. This highly reactive molecule is synthesized
from L-arginine by a group of isoenzymes collectively
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isoforms, the constitutive endothelial (eNOS) and neuro-
nal (nNOS) NOS isoforms, and the inducible NOS variant
(iNOS). [9-12]. The physiological role of NO can be exam-
ined by blocking NOS using some efficient inhibitors such
as N-Nitro-L-arginine methyl ester (L-NAME) and ami-
noguanidine. L-NAME is a competitive and non-selective
inhibitor of NOS [13]. Aminoguanidine inhibits particu-
larly the inducible NOS isoform [14]. Our group has pre-
viously demonstrated the participation of NO, by usage of
those NOS inhibitors, in the pathogenesis of oral mucosi-
tis induced by 5-fluorouracil [15].
Although NO is important in host defense and home-
ostasis, it is also regarded as harmful and has been
implicated in the pathogenesis of a wide variety of
inflammatory and autoimmune diseases [10]. NO exerts
its effects directly or via the formation of potent oxi-
dants [16]. During inflammatory reactions, large
amounts of NO and superoxide are formed and may
lead to the peroxynitrite anion, a toxic product of NO
combined with superoxide, which can nitrate the pheno-
lic ring of tyrosine residues in proteins [17]. Accord-
ingly, a recent study by Kolli et al demonstrated that
n i t r o s a t i v es t r e s sm a yp l a yar o l ei nM T X - i n d u c e d
intestinal damage. Following treatment with MTX, they
found increased staining of nitrotyrosine and of nitrate
levels in the intestinal samples, which was accompanied
by neutrophil infiltration [18]. However, the specific role
of the inducible form of NOS and the effect of NOS
inhibitors was not evaluated.
Thus, the aim of this study was to investigate the
effect of nitric oxide (NO) on the pathogenesis of meth-
otrexate-induced intestinal mucositis, looking at specifi-
cally the role of the inducible form of iNOS and the
effect of NOS inhibitors.
2. Methods
2.1. Animals
Forty-eight male Wistar rats, weighing 140 to 160 g,
were obtained from the Federal University of Ceará and
eight C57BL/6 inducible nitric oxide synthase knock-out
mice (iNOS
-/- ) and corresponding wild-type animals
(iNOS
+/+), weighing 22 to 25 g, were obtained from the
Animal Facility located at the Faculty of Medicine of
Ribeirão Preto, University of São Paulo. All animals
were housed in temperature-controlled rooms and
received water and food ad libitum. Surgical procedures
and animal treatments were conducted in accordance
with the Institutional Animal Care and Use Committee
guidelines from both Universities.
2.2. Materials
N-Nitro-L-Arginine Methyl Ester (L-NAME), aminogua-
nidine and L-arginine were purchased from Sigma-Aldrich
(St. Louis, MO, U.S.A.). The methotrexate (MTX) used in
this study is a product of Faulding (Maine, Australia).
Rabbit anti-NOS-2 and Biotinylated goat anti-rabbit were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, U.S.A). Rabbit anti-nitrotyrosine was purchased from
Upstate
® (Lake Placid, NY, U.S.A). Mouse anti-rat Ki67
and biotinylated rabbit anti-mouse were purchased from
DakoCytomation. Vectastatin
® ABC detection system and
the VIP substrate kit used in immunohistochemistry were
obtained from Vector Laboratories (Burlingame, CA, U.S.
A.). The apoptosis assay was performed using the Apop-
Tag Peroxidase In Situ Detection Kit (Chemicon Interna-
tional, USA). Proteinase K was from Sigma-Aldrich
(St. Louis, MO, U.S.A.).
2.3. Induction of Experimental Intestinal Mucositis
Intestinal mucositis was induced by three subcutaneous
(s.c.) MTX administrations on the first three days of the
experiment (2.5 mg/kg), according to a model previously
described [19] and modified by our laboratory. The ani-
mals were sacrificed on the 5
th day after the first injec-
tion of MTX, under deep anesthesia with chloral
hydrate (250 mg/kg, i.p.).
2.4. Experimental design
The Wistar rats groups with intestinal mucositis were
treated intraperitoneally (i.p.) with either the NOS inhibi-
tors aminoguanidine (10 mg/Kg) or L-NAME (20 mg/Kg),
one hour before the mucositis induction and daily until
sacrifice (on the 5
th day). Control groups including ani-
mals not subjected to intestinal mucositis (control) and a
group which was subjected to the experimental mucositis
and received saline i.p. (MTX).
In another set of experiments, iNOS
-/- and wild-type
mice (iNOS
+/+) were divided into 4 groups of 4 animals
each, as follow: knock-out animals submitted to intestinal
mucositis (iNOS
-/-/MTX), a group of wild-type mice
which was also submitted to intestinal mucositis (iNOS
+/+/MTX) and two control groups consisting of knock-
out mice and corresponding wild-type animals not sub-
jected to intestinal mucositis (iNOS
-/-/control and iNOS
+/+/control, respectively).
2.5. Histopathology Analysis
On day 5, after killing, the intestines (duodenum, jeju-
num and ileum) were dissected. In each experiment,
samples were removed for histopathological analysis. The
specimens were fixed in 10% (v/v) neutral-buffered for-
malin, dehydrated and embedded in paraffin. Sections
were cut and stained with haematoxylin and eosin (H&E)
and examined by light microscopy (Leica DM LS 2 -
Wetzlar, Germany) by an experienced histologist blinded
to the experimental groups and damage extent. The
severity of mucositis was graded using a modification of
Leitão et al. BMC Gastroenterology 2011, 11:90
http://www.biomedcentral.com/1471-230X/11/90
Page 2 of 10the Macpherson and Pfeiffer histopathological grading
system [20] previously described [21], considering micro-
scopic findings such villus and crypt integrity, inflamma-
tory cell influx, vacuolization and edema. (Table 1).
2.6. Intestinal Morphometry
Villus height was measured from hematoxylin and eosin
slides on a light microscope equipped with a high-resolu-
tion digital camera Leica DFC 320 (Wetzlar, Germany),
connected to a computer with an image captured pro-
gram. Villus height was measured from the baseline to
the villus tip. At least 10 clear longitudinal villi sections
were selected and counted for each sample (six samples
for each group). All morphometric measurements were
done blindly with Leica Measure Software (Wetzlar,
Germany).
2.7. Myeloperoxidase assay
Segments of duodenum, jejunum and ileum were stored
at -70°C until required for the assay. After homogeniza-
tion and centrifugation (4,500 G, 20 min), myeloperoxi-
dase activity associated with neutrophil azurophilic
granules was determined by a colorimetric method
described previously [22]. Results were reported as MPO
units/mg of tissue. The unit of MPO activity was defined
as the one converting 1 μmol/min of hydrogen peroxide
into water at 22°.
2.8. Cell proliferation and cell death
Methotrexate-induced cell death was investigated on the
5
th day using TdT-mediated dUTP nick end-labeling
(TUNEL) method. Briefly, paraffin-embedded jejunal sec-
tions were rehydrated and incubated with 20 μg/mL of
proteinase K for 15 minutes at room temperature. Endo-
genous peroxidase was blocked by treating with 3% (v/v)
hydrogen peroxide in PBS for 5 minutes at room tem-
perature. After washing, sections were incubated in a
humidified chamber at 37°C for 1 h with TdT buffer con-
taining TdT enzyme and reaction buffer. Specimens were
incubated for 10 minutes at room temperature with a
stop/wash buffer and then incubated in a humidified
chamber for 30 minutes with anti-digoxigenin peroxidase
conjugate at room temperature. After a series of PBS
washes, slides were covered with peroxidase substrate to
develop color and then washed in three changes of dH2O
and counterstained in 0.5% (w/v) methyl green for 10
minutes at room temperature. The TUNEL positive cells
were counted (10 fields per slide; x1000) in order to per-
form a statistical comparison.
Crypt cell proliferation was assessed on the 5
th day by
Ki67 immunohistochemistry, a nuclear antigen that is
present in proliferating cells but absence in quiescent
cells [23,24]. Jejunum tissues from each experimental
group were immunostained using the streptavidin-bio-
tin-peroxidase method, as described elsewhere [25]. The
Ki67 positive cells were counted (10 fields per slide;
x1000) in order to perform a statistical comparison.
2.9. Immunohistochemistry for iNOS and nitrotyrosine
Nitrotyrosine and iNOS immunohistochemistry was per-
formed using the streptavidin-biotin-peroxidase method
[25]. Briefly, sections were deparaffinized and rehydrated
through xylene and graded alcohols. After antigen retrie-
val, endogenous peroxidase was blocked (15 min) with
3% (v/v) hydrogen peroxide and washed in phosphate-
buffered saline (PBS). Sections were incubated overnight
(4°C) with either a primary rabbit anti-iNOS antibody
diluted 1:200 or rabbit anti-nitrotyrosine antibody diluted
1:400 in PBS plus bovine serum albumin (PBS-BSA).
Slides were then incubated with biotinylated goat anti-
rabbit; diluted 1:200 in PBS-BSA. After washing, slides
were incubated with avidin-biotin-horseradish peroxidase
conjugate (Strep ABC complex by Vectastain
® ABC
Reagent and peroxidase substrate solution) for 30 min-
utes, according to the Vectastain protocol. iNOS was
visualized with the chromogen 3.3’diaminobenzidine
(DAB). Negative control sections were processed simulta-
neously, as described above, but with the first antibody
replaced by PBS-BSA 5%. None of the negative controls
showed iNOS or nitrotyrosine immunoreactivity. Slides
were counterstained with Harry’s hematoxylin.
2.10. Statistical Analysis
Data were described as either means ± SEM or median,
as appropriate. Analysis of Variance (ANOVA) followed
by Bonferroni’s test was used to compare means and
Kruskal-Wallis and Dunns tests to compare medians;
P < 0.05 was defined as statistically significant.
3. Results
3.1. Histopathology and Morphometry analysis
MTX administration induced a significant (p < 0.05) villus
atrophy in all three small intestinal segments (duodenum,
Table 1 Histopathological grading scores
Scores Microscopic findings
0 Normal histological findings
1 Mucosa: villus blunting, loss of crypt architecture,
sparse inflammatory cell infiltration, vacuolization
and edema.
Normal muscular layer
2 Mucosa: villus blunting with fattened and vacuolated cells,
crypt necrosis, intense inflammatory cell infiltration,
vacuolization and edema
Normal muscular layer
3 Mucosa: villus blunting with fattened and vacuolated cells,
crypt necrosis, intense inflammatory cell infiltration,
vacuolization and edema
Muscular: edema, vacuolization, sparse neutrophil infiltration
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Page 3 of 10jejunum and ileum) when compared with the group not
subjected to intestinal mucositis (control) (Figure 1). The
villi from MTX-treated rats exhibited flattened and vacuo-
lated cells. Additionally, the histopathology revealed crypt
necrosis and inflammatory infiltration within the lamina
propria, constituted by mononuclear and polimorphonuc-
lear cells in the MTX group (Figure 2). Both aminoguani-
dine and L-NAME prevented the villus atrophy in the
duodenum and jejunum, observed on day 5. Aminoguani-
dine, but not L-NAME, significantly prevented the villus
atrophy in the ileum (Figure 1). Both aminoguanidine and
L-NAME reduced villus blunting and crypt necrosis in the
three intestinal segments as can be clearly observed in
representative jejunal section seen in Figure 2.
The histopathology of the small bowel segments (duo-
denum, jejunum and ileum) of animals subjected to
MTX-induced intestinal mucositis, on day 5, showed
accentuated villus blunting, covered with flattened and
vacuolated cells, crypt necrosis, intense inflammatory
cell infiltration, and edema both in mucosa and muscu-
lar (MTX histopathological score 3; control histopatho-
logical score 0) (control-Figure 2A and 2B; MTX-
Figure 2C and 2D; Table 2). The treatment with both
aminoguanidine (Figure 2E and 2F; Table 2) and L-
NAME (Figure 2G and 2H; Table 2) significantly (p <
0.05) reduced villus and crypt damages and inflamma-
tory alterations in the all three small intestine segments
when compared to MTX group (MTX histopathological
score 3; AG and L-NAME histopathological score 1)
(Figure 2A and 2B; Table 2).
3.2. Mieloperoxidase activity
MPO activity was significantly increased (p < 0.05) by
the treatment with MTX in the all three small intest-
inal segments (duodenum, jejunum and ileum) in com-
parison to the untreated control group (control). Both
aminoguanidine (10 mg/Kg) and L-NAME (20 mg/Kg)
significantly (p < 0.05) reduced MTX-induced increase
in MPO activity in duodenum, jejunum and ileum
(Figure 3).
A significant (p < 0.05) increase in the jejunal MPO
activity was observed in wild-type mice subjected to
intestinal mucositis due to MTX treatment (iNOS
+/+/MTX) in contrast to the control group, which
received saline (iNOS
+/+/control). MTX did not cause
any inflammatory activity in the jejunum from inducible
nitric oxide synthase (iNOS
-/-) knock-out mice. The
MPO activity was similar to the iNOS
-/-/control, as well
as to the wild-type iNOS
+/+/control (p > 0.05) (Table 3).
3.4. Cell proliferation and cell death
MTX-challenged jejunum showed a significant increase
(p < 0.05) of TUNEL positive cells in the lamina pro-
pria, when compared to untreated control. Either
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Figure 1 Effect of aminoguanidine and L-NAME on MTX-induced
villus atrophy in the duodenum (A), jejunum (B), and ileum (C).
Bars represent the mean value ± standard error of the mean (SEM) of
the villus height in each segment. *p < 0.05 represents statistical
differences compared to control group. **p < 0.05 represents statistical
differences compared to MTX group treated with saline (-). The
number of animals in each group was at least six. Data were analyzed
by using analysis of variance (ANOVA) and Bonferroni tests.
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Figure 2 Representative photomicrographies of normal jejunum showing the region of villi (A) and crypt (B); jejunum of MTX treated
rat showing blunted villous recovered with flattened and vacuolated cells, and presenting inflammatory cell infiltration on the lamina
propria (C) and crypt necrosis with neutrophil infiltration (D); systemic administration of aminoguanidine (E and F) and L-NAME (G
and H) reduced the villus height atrophy as well as crypt destruction in the segments of jejunum. Hematoxylin and eosin staining.
Magnification 400x. Scale bar lengths 10 μm. The arrow indicates neutrophils within a necrotic crypt.
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Page 5 of 10aminoguanidine or L-NAME treatment substantially
(p < 0.05) reduced the number of TUNEL positive
cells in the lamina propria. When TdT enzyme was
replaced by the reaction buffer, TUNEL positive cells
were no longer detected (Figure 4A).
Figure 4B illustrates jejunum crypt cell proliferation
(by Ki67 expression) in the four experimental groups.
Treatment with MTX significantly (p < 0.05) reduced
the number of Ki67 positive cells compared to control
animals. This MTX effect was reversed by aminoguani-
dine but not by L-NAME treatment.
3.5. Immunohistochemical reaction for iNOS and
nitrotyrosine
MTX-treated rats presented intense iNOS immunostaining
in the jejunum enterocytes, lamina propria cells (Figure
5G), and neutrophils (Figure 5I; black arrow) and other
inflammatory cells surrounding and within necrotic crypts
(Figure 5I), when compared to the weak immunostaining
of villus and crypt regions from unchallenged rats (Figure
5C and 5E). When the iNOS antibody was replaced by 5%
PBS/BSA no immunostaining was detected (Figure 5A).
Rats receiving subcutaneous MTX presented intense
immuno-labeling in the jejunum for nitrotyrosine both in
enterocytes and lamina propria cells (Figure 5F), in con-
trast to the weak immunostaining seen in the unchal-
lenged jejuni (Figure 5D). Either aminoguanidine (Figure
5H) or L-NAME (Figure 5J) treatment considerably
reduced the immunostaining for nitrotyrosine. When
nitrotyrosine antibody was replaced by 5% PBS/BSA no
immunostaining was detected (Figure 5B).
4. Discussion
This study demonstrates that treatment with aminogua-
nidine and L-NAME, both NOS inhibitors, significantly
prevented MTX-induced intestinal damage, such as vil-
lous atrophy, crypt necrosis and neutrophil infiltration,
Table 2 Effect of aminoguanidina (AG) and L-NAME on
microscopic findings of duodenum, jejunum and ileum of
animals submitted to methotrexate (MTX)-induced
intestinal mucositis, observed on 5
th day
Duodenum Jejunum Ileum
Control 0 (0-0) 0 (0-0) 0 (0-0)
MTX 3 (3-3)* 3 (3-3)* 3 (3-3)*
AG 1 (1-1)*, ** 1 (1-1)*, ** 1 (1-1)*, **
L-NAME 1(1-2)*, ** 1 (1-1)*, ** 1 (1-1)*, **
Intestinal mucositis was carried out by three subcutaneous MTX injections
(2.5 mg/kg) in Wistar rats. Rats were treated intraperitoneally with the NOS
inhibitors aminoguanidine (AG; 10 mg/Kg) or L-NAME (20 mg/Kg), one hour
before MTX injection and daily until sacrifice, on the fifth day. Data represents
the median values (and range) of microscopic scores in at least 10 animals
per group. *p < 0.05 compared to normal animals (control group); **p < 0.05
compared to animals submitted to MTX-induced intestinal mucositis that
received saline, observed on the 5
th day. Data were analysed by using
Kruskal-Wallis and Dunn’s test.
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Figure 3 Effect of aminoguanidine and L-NAME on
myeloperoxidase (MPO) activity in the duodenum, jejunum
and ileum segments of rats submitted to intestinal mucositis.
Bars represent the mean value ± standard error of the mean (SEM)
of the MPO units/mg of tissue. *p < 0.05 represents statistical
differences compared to MTX group (-). The number of animals in
each group was at least six. Data were analyzed by using analysis of
variance (ANOVA) and Bonferroni tests.
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that suggested that nitrosative stress may play a role in
MTX-induced mucositis [18]. The participation of NO
in our model is supported by the increased iNOS
expression in the intestinal tissue following MTX treat-
ment. Furthermore, no significant inflammatory activity
was found in jejunum of iNOS
-/- animals, as demon-
strated by MPO assay.
Intestinal mucositis is a dose limiting side-effect of can-
cer chemotherapy, which leads to decreased absorption of
nutrients, increased epithelial permeability, recurrent diar-
rhea, and weight loss [1]. MTX is a well-known cause of
intestinal mucositis, which impairs rapidly dividing cells,
such as epithelial stem cells within intestinal crypts,
thereby causing diminished enterocyte replacement. Our
group has previously demonstrated that MTX administra-
tion in rats causes villous atrophy with consequent reduc-
tion of the overall mucosal absorptive surface area [5]. It is
well established that pro-inflammatory cytokines, such as
interleukin-1 (IL-1), tumor necrosis alpha (TNF-a)a n d
interleukin-6 (IL-6) are potent inducers of iNOS in a wide
variety of cells types, with consequent production of NO
[26,27]. Although the participation of pro-inflammatory
cytokines in the intestinal mucositis has been shown
[28,29], the role of nitric oxide is not fully understood.
It has been demonstrated that nitric oxide is an impor-
tant mediator of 5-FU-induced oral mucositis [15], suggest-
ing that chemotherapy-induced nitric oxide synthase
(iNOS) activation may play a critical role in mucosal injury.
In accordance, the present study demonstrates increased
iNOS expression in jejunal samples as seen by immunohis-
tochemistry, following treatment with MTX. Several stu-
dies have shown that sustained release of NO, as a result of
iNOS upregulation, can lead to cellular damage and gut
barrier failure [30] as reported in the experimental 2,4,6-
trinitrobenzenesulfonic acid (TNBS)-induced colitis model
in rats [31] and in guinea pig ileitis [32].
The iNOS immunostaining was particularly observed
in neutrophils inside and surrounding the necrotic crypt,
suggesting that NO produced by these cells is involved in
the mucosa damage. The role of neutrophils on the
MTX-induced intestinal mucositis was confirmed by
increased MPO activity in all intestinal segments. We
also observed that L-NAME and aminoguanidine protec-
tive effects were associated with reduced neutrophil
Table 3 Myeloperoxidase (MPO) activity in the jejunum
segment from inducible nitric oxide synthase knock-out
mice (iNOS
-/-) and C57BL/6 wild-type animals (iNOS
+/+)
submitted to intestinal mucositis
iNOS
+/+/control
iNOS
+/+/MTX
iNOS
-/-control iNOS
-/-/MTX
Mean ±
Std. error
0.056 ± 0.01 8.45 ± 0.60 * 0.035 ± 0.02 0.056 ± 0.001
Intestinal mucositis was induced by subcutaneous administration of MTX.
After sacrifice, on the 5
th day, a sample of the jejunum segment was
harvested for MPO activity assay. *p < 0.05 represents statistical differences
compared to iNOS
+/+/control group. The number of animals in each group
was at least four. Data were analyzed by using analysis of variance (ANOVA)
and Bonferroni tests.
Control -A G L-NAME
0
20
40
60
80
100
120
           MTX
*
** **
T
U
N
E
L
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
/
f
i
e
l
d A
Control -A G L-NAME
0
10
20
30
MTX
*
*
*
**
K
i
6
7
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
/
f
i
e
l
d B
Figure 4 Effect of aminoguanidine and L-NAME on cell death
and proliferation in the jejunum segments. An increased
number of TUNEL positive cells is observed in jejunum of rats
submitted to MTX-induced intestinal mucositis when compared to
the jejunum of a normal control rat. The treatment with
aminoguanidine or L-NAME significantly reduced the number of
TUNEL positive cells in the lamina propria (A). The treatment with
MTX result in a significant decrease in the number of Ki67 positive
cells compared to control animals. Aminoguanidine administration,
but not L-NAME, result in a significant increase in the number of
Ki67 positive cells compared to the MTX group (B). Bars represent
the mean value ± standard error of the mean (SEM) of the tunel
positive cells (A) and Ki67 positive cells (B). The TUNEL and Ki67
positive cells were counted (10 fields per slide; x1000) in order to
perform a statistical comparison. *p < 0.05 represents statistical
differences compared to control group. **p < 0.05 represents
statistical differences compared to MTX group (-). Data were
analyzed by using analysis of variance (ANOVA) and Bonferroni tests.
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Figure 5 Representative examples of iNOS (left) and nitrotyrosine (right) immunohistochemistry of rat jejunum. The jejunum tissue of
rats which received subcutaneous MTX presented intense immunostaining for iNOS, both in epithelial cells recovering the villi as well as in the
lamina propria cells (G) and in the neutrophils (I; arrow) and other inflammatory cells surrounding and inside the necrotic crypts (I), when
compared to the weak immunostaining in the jejunum villous and crypt region of a normal control rat (C and E). Negative control represents a
sample of the jejunum where the antibody for iNOS was replaced by 5% PBS/BSA and no immunostaining was detected (A). The jejunum tissue
of rats which received subcutaneous MTX presented intense immunostaining for nitrotyrosine in the lamina propria cells (F; yellow arrow), when
compared to the weak immunostaining in the jejunum lamina propria and crypt region of a normal control rat (D). The treatment with
aminoguanidine (H) or L-NAME (J) considerably reduced the immunostaining for nitrotyrosine. Negative control represents a sample of the
jejunum where the antibody nitrotyrosine was replaced by 5% PBS/BSA and no immunostaining was detected (B). Magnification 400x. Scale bar
lengths 10 μm. The yellow arrow indicate nitrotyrosine immunostained cells.
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Page 8 of 10infiltration (as seen as histopathology and MPO activity),
suggesting that NOS inhibition might lead to poor
neutrophil infiltration. A recent study by our group
demonstrated that aminoguanidine and 1400 W reduced
neutrophil infiltration in 5-FU-induced oral mucositis
[15]. Indeed, the role of NO on neutrophil migration is
still controversial, NO downregulates the expression of
adhesion molecules in the vascular endothelium, there-
fore decreasing neutrophil trafficking into inflamed tis-
sues [33,34]. On the other hand, in the rat skin, L-NAME
can inhibit the edema formation induced by carrageenin,
an inflammatory agent that promotes increased vascular
permeability and massive leukocyte emigration, suggest-
ing a pro-inflammatory role for NO in this model [35].
Moreover, during inflammatory reactions when large
amounts of NO and superoxide are formed, the combina-
tion of both leads to the formation of reactive nitrogen
species, such as the peroxynitrite [36]. This toxic com-
pound has the ability to initiate lipid peroxidation, sulfhy-
dryls oxidation, and readily nitrates phenolic compounds
such as tyrosine residues on proteins [17,36-39], resulting
in augmented inflammation and tissue injury. In this
regard, we detected a significant increase of nitrotyrosine
immunostaining in the intestinal segments of rats on the
fifth day of the MTX-induced intestinal mucositis, rein-
forcing the role of NO via peroxynitrite on intestinal
mucositis. Thus, the decrease in the neutrophil migration
observed when aminoguanidine and L-NAME were
administered to MTX-treated rats is probably related to
suppression of peroxynitrite formation. Sustained iNOS
upregulation, leading to increased NO levels, via peroxy-
nitrite, has been shown to play a major role in the initia-
tion of the intestinal mucosal injury in stressful
conditions, such as endotoxemia, hemorrhagic shock, or
necrotizing enterocolitis, causing enterocyte apoptosis
and disruption of the intestinal barrier and increased bac-
terial translocation [40]. In the present study we demon-
strate the role of NO on the peak of inflammation and
tissue damage (5th after MTX-injection), which likely
corresponds to the signal amplification/ulcerative phase
of mucositis.
It is well known that high concentration of NO induces
apoptosis in various cells including intestinal epithelial
cells [40-43]. Accordingly, we found a significant increase
in TUNEL-positive cells in the jejunum of rats following
treatment with MTX compared to untreated controls.
Both aminoguanidine and L-NAME were able to prevent
cell death, as detected by the TUNEL assay. Additionally,
we demonstrated that MTX significantly decreased the
number of Ki67 positive cells indicating a reduction of
proliferation. The treatment with AG, the more selective
iNOS inhibitor, prevented the inhibitory effect of MTX
on proliferation, suggesting that high levels of NO pro-
duced by iNOS may contribute to anti-proliferative
action of MTX. Accordingly, the literature has shown a
proliferative effect of AG in T-84 cell [44]. It has been
reported that NO, via peroxynitrate, alters proliferative
signaling mediated by protein tyrosine kinase, decreasing
enterocyte proliferation which, in combination with NO-
induced cell death, may contribute to gut barrier disrup-
tion [45]. As expected, L-NAME did not prevent the
inhibitory effect of MTX on cell proliferation, since
L-NAME itself may decrease cell proliferation in the
intestinal epithelium [46].
Conclusion
We have demonstrated that treatment with MTX
induced intestinal epithelial damage in wild type rats
and did not show a significant effect on intestinal
inflammation in iNOS
-/- mice. The intestinal damage
was prevented by NOS inhibitors L-NAME and AG.
T h e s ef i n d i n g ss u g g e s tac r i t i c a lr o l eo fN O ,v i at h e
inducible iNOS, in MTX-induced intestinal mucositis.
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